Great EU-funded Innovations


Improvements on the PVDF membrane production and derivative applications of technology for the purification of monoclonal antibodies

Market Maturity

Exploring: These are innovations that are actively exploring value creation opportunities.More about market maturity categories

Innovation topic

Excellent Science

Date of analysis

Innovation Radar's analysis of this innovation is based on data collected on 14/11/2017

Go to market needs

Needs that, if addressed, can increase the chances this innovation gets to (or closer to) the market incude:

  • Prepare for Market entry
  • Secure capital
  • Scale-up market opportunities
  • Project

    This innovation was developed under the Horizon 2020 project AMECRYS. Details of this project are provided below:

    Project acronym: AMECRYS

    Project Title: Revolutionising Downstream Processing of Monoclonal Antibodies by Continuous Template-Assisted Membrane Crystallization

    Project description: Separation and purification of biopharmaceuticals is today one of the most time and cost intense Downstream Processing (DSP) operations in the manufacture of commercial products. Separation and purification of proteins is usually achieved chromatographically, with all of its disadvantages including high buffer requirements, large footprint, reuse and storage of resin studies as well as costs. Traditional DSP based on batch chromatography contribute ca. 66% of the total production cost of anti-cancer monoclonal antibodies (mAbs). Largely contributing to this is the cost of chromatography media; for instance, the cost of 1 L of protein A resin with binding capacity of 20-70 g mAb is about 25000 Eur. By a visionary and ambitious combination of the emerging Continuous Manufacturing Paradigm with innovative Membrane Crystallization Technology and the selective nanotemplate-recognitions directly from the fermentation broth, the AMECRYS Network aims to develop a new Continuous Template-Assisted Membrane Crystallizer in order to revolutionize the DSP platform for mAbs production, thus achieving unprecedented purification and manufacturing efficiencies. Major research challenges will include: i) the synthesis of 3D-nanotemplates with specific molecular recognition ability towards mAbs from complex solutions; ii) the development of tailored macroporous fluoropolymer membranes for advanced control of selective heterogeneous nucleation; iii) the design of multilevel microfluidic devices for high-throughput mAb crystallization screening in a wide range of conditions under continuous flow (“pharma-on-a-chip” concept); iv) technology scale-up to a L-scale continuous prototype designed with recognition of QS/GMP compliance for biopharmaceuticals. The replacement of chromatography with a single membrane-crystallization unit will lead to >60% CapEx and O&M costs decrease, 30-fold footprint reduction and high-purity solid formulation of mAbs with preserved biological activity.

    Project end date: 30/09/2020

    More info:

    • Read more about this project on CORDIS (find names of contact persons and their phone numbers on the CORDIS page)

    • Details of this project on the Horizon 2020 dashboard

    Key Innovator(s)


    ROMA, IT

    Higher Education Institute / Research Centre